Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Gastroesophageal Cancer Market $24.1 Billion by 2031

The global market for gastroesophageal cancer projected to reach $24.1 billion by 2031, expanding at a double-digit CAGR of 10.5% over the forecast period, driven by tobacco and alcohol use, nutritional habits and increasing incidence of obesity and gastroesophageal reflux.

Global Gastroesophageal Cancer Market

Gastroesophageal cancer (GEC), comprising proximal esophagogastric junction (EGJ) and distal gastric cancer (GC), is a significant public health concern.

  • The most common types of esophageal cancer are squamous cell carcinoma (SCC/GC) and adenocarcinoma (AC/EGJ).
  • Squamous cell carcinoma is the most prevalent esophageal cancer worldwide, whereas adenocarcinoma is the most common form of esophageal cancer in the United States.
    • Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Incidence rates vary within different geographic locations.
      • In some regions, higher rates of esophageal cancer cases may be attributed to tobacco and alcohol use or particular nutritional habits and obesity.

The epidemiology of these tumors has significantly changed over the past several decades especially in developed countries.

  • Gastroesophageal reflux disease and Barrett esophagus may increase the risk of esophageal adenocarcinoma.
    • Esophageal cancer is often diagnosed at an advanced stage because there are no early signs or symptoms.
      • Smoking and heavy alcohol use increase the risk of esophageal squamous cell carcinoma.

There is a recognized decrease in incidence and mortality of distal GC and an increase in incidence and mortality of proximal EGJ cancer.

  • The changing epidemiology is thought to be mainly due to changing trends of risk factors such as lower incidence of Helicobacter pylori infection and increasing incidence of obesity and gastroesophageal reflux.
    • Gastric ulcer disease, atrophic gastritis, and pernicious anemia are also conditions that are associated with increased risk of developing GC.

Despite significant progress in multimodality treatment options, the overall prognosis remains poor, and 5-year survival rates for all-comers are still below 20%. The combination of traditional systemic therapy with new biologicals and/or targeted agents is one of these new treatment options. Some of these agents are already approved, while others are currently undergoing clinical trials.

  • In the setting of disease localized to the primary site and regional nodes, the use of chemotherapy (CT) or radiation therapy (RT) alone has resulted in a significant improvement in outcome.
  • The drugs approved by US FDA for esophageal cancer includes Docetaxel, Taxotere (docetaxel), Cyramza (ramucirumab), Herceptin (trastuzumab), Ramucirumab, and Trastuzumab.
    • The drug combination used in esophageal cancer treatment are FU-LV (Fluorouracil and Leucovorin Calcium) and XELIRI [Capecitabine (Xeloda) and Irinotecan Hydrochloride].
    • First-line of treatment includes human epidermal growth factor receptor 2 (HER2) inhibitor trastuzumab (Herceptin) with chemotherapy.
    • Vascular endothelial growth factor receptor 2 (VEGFR2), ramucirumab (Cyramza), is approved as a second-line treatment.
    • Programmed cell death 1 ligand 1 (PDL1) inhibitor, pembrolizumab (Keytruda) was granted accelerated approval by the FDA for the third-line treatment.
    • PD1 inhibitor nivolumab (Opdivo) received approval in Japan for unresectable, advanced or recurrent gastric cancer.
  • In 2021, FDA approved the antibody-drug conjugate fam-trastuzumab deruxtecan for the treatment of advanced HER2-positive gastric or GEJ adenocarcinoma after prior trastuzumab-containing chemotherapy.
  • The drug market for gastroesophageal cancer is set to change substantially in the coming years, largely because of the efficacy of immune checkpoint inhibitor therapies, particularly PD-1 inhibitors (Opdivo and Keytruda).
  • Numerous targeted therapies are also in late-stage development.

Therapies in phase III development for gastroesophageal cancer include Andecaliximab, Avelumab (Bavencio), IMAB362, Ipilimumab (Yervoy), Napabucasin, Nimotuzumab, Pamiparib, Regorafenib (Stivarga), Rivoceranib (Apatinib), S-1 and folinic acid (TAS-118), S588410, Tislelizumab, Trifluridine and tipiracil (Lonsurf).

The global market for gastroesophageal cancer research report provides market size ($million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031).

The global market for gastroesophageal cancer drugs segmented by drug class (angiogenesis inhibitors, CTLA4 inhibitors, cytotoxic agents, HER2 inhibitors, MMP9 inhibitors, PD1 inhibitors, PDL1 inhibitors); and by geography.

The global market for gastroesophageal cancer research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In the United States, esophageal cancers represent the fifth most common gastrointestinal cancer with about 17,000 cases per year and are the sixth most common cancer worldwide.
  • The highest-risk area includes portions of northern Iran, southern Russia, central Asian countries, and northern China where squamous cell cancers dominate all cases by 90%.
    • In contrast, the United States is considered a low-risk area with an increase in the incidence of esophageal adenocarcinoma mostly due to an upsurge of obesity and GERD, and conversely a steady decrease in squamous cell carcinoma because of the long-term reduction in tobacco use and alcohol consumption.

In addition, the global market for gastroesophageal cancer report provides the detailed market landscape (market drivers, restraints, and opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global gastroesophageal cancer market and profiled in this report include Astellas Pharma, Inc., Bayer AG, BeiGene, Ltd., Boston Biomedical, Inc., Bristol-Myers Squibb and Company, Celgene Corporation, Daiichi Sankyo Co., Ltd., Gilead Sciences, Inc., LSK BioPartners, Inc. (LSK BioPharma), Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., Pfizer, Inc., Servier Laboratories , Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., and Taiho Oncology, Inc.

  • Drug Class
    • Angiogenesis inhibitors
    • CTLA4 inhibitors
    • Cytotoxic agents
    • HER2 inhibitors
    • MMP9 inhibitors
    • PD1 inhibitors
    • PDL1 inhibitors
  • Geography 
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Astellas Pharma, Inc.
    • Bayer AG
    • BeiGene, Ltd.
    • Boston Biomedical, Inc.
    • Bristol-Myers Squibb and Company
    • Celgene Corporation
    • Daiichi Sankyo Co., Ltd.
    • Gilead Sciences, Inc.
    • LSK BioPartners, Inc. (LSK BioPharma)
    • Merck & Co., Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer, Inc.
    • Servier Laboratories 
    • Shionogi & Co., Ltd.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Taiho Oncology, Inc.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com